No abstract available
Keywords:
ACE inhibitors; ARBs; Adempas; Bidil; Entresto; Verquvo; adverse effects; beta blockers; bisoprolol; carvedilol; dapagliflozin; diuretics; dosage; drug interactions; efficacy; empagliflozin; eplerenone; heart failure; hydralazine; isosorbide dinitrate; lactation; metoprolol; pregnancy; riociguat; sacubitril; safety; spironolactone; valsartan; vericiguat.
MeSH terms
-
Cardiovascular Agents / administration & dosage
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / therapeutic use*
-
Drug Interactions
-
Heart Failure / drug therapy*
-
Heterocyclic Compounds, 2-Ring / administration & dosage
-
Heterocyclic Compounds, 2-Ring / adverse effects
-
Heterocyclic Compounds, 2-Ring / therapeutic use*
-
Humans
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Randomized Controlled Trials as Topic
Substances
-
Cardiovascular Agents
-
Heterocyclic Compounds, 2-Ring
-
Pyrimidines
-
vericiguat